Introduction {#s1}
============

Peptidoglycan, the major component of bacterial cell walls, is a giant (10^9^ to 10^10^ Da) net-like macromolecule composed of glycan strands cross-linked by short peptides ([@bib32]) ([Figure 1](#fig1){ref-type="fig"}). The glycan strands are polymerized by glycosyltransferases and the cross-links are formed by D,D-transpeptidases. The latter enzymes cleave the D-Ala^4^-D-Ala^5^ peptide bond of an acyl donor stem and link the carbonyl of D-Ala^4^ to the side chain amine of diaminopimelic acid (DAP) of the acceptor stem, thereby generating D-Ala^4^→DAP^3^ cross-links ([Figure 1A](#fig1){ref-type="fig"}) ([@bib23]). β-lactam antibiotics mimic the D-Ala^4^-D-Ala^5^ termination of peptidoglycan precursors and inactivate the D,D-transpeptidases by acting as suicide substrates ([@bib29]). The D,D-transpeptidases belong to a diverse family of proteins, commonly referred to as penicillin-binding proteins (PBPs), that fall into three main classes ([@bib24]). Class A PBPs (PBP1a, 1b, and 1c) combine glycosyltransferase and D,D-transpeptidase modules. Class B PBPs (PBP2 and 3) are composed of a nonenzymatic morphogenesis module fused to a D,D-transpeptidase module. Class C PBPs (PBP4, 4b, 5, 6, 6b, 7, and AmpH) are monofunctional enzymes with D,D-carboxypeptidase and endopeptidase activities that hydrolyze the D-Ala^4^-D-Ala^5^ bond of pentapeptide stems and the D-Ala^4^→DAP^3^ bond of cross-linked peptidoglycan, respectively. Peptidoglycan polymerization involves two complexes ([Figure 1B](#fig1){ref-type="fig"}), the divisome and the elongasome, responsible for septum formation and lateral cell-wall elongation, respectively ([@bib8]). These complexes include all the biosynthetic and hydrolytic enzymes required for the incorporation of new subunits into the expanding peptidoglycan net, as well as cytoskeletal proteins, MreB and FtsZ, acting as guiding devices.10.7554/eLife.19469.002Figure 1.Peptidoglycan synthesis in *E. coli*. (**A**) Reactions catalyzed by enzymes involved in peptidoglycan polymerization and Braun lipoprotein anchoring. (**B**) Complexes responsible for peptidoglycan synthesis during lateral cell-wall growth and division.**DOI:** [http://dx.doi.org/10.7554/eLife.19469.002](10.7554/eLife.19469.002)

Unusual cross-links connecting two DAP residues were detected in *E. coli* as early as 1969, however the enzymes responsible for their formation at that time were unknown ([@bib26]). These DAP^3^→DAP^3^ cross-links account for 3% and 10% of the cross-links present in the peptidoglycan extracted from bacteria in the exponential and stationary phases of growth, respectively ([@bib26]). More recently, we have identified the L,D-transpeptidases (Ldt) responsible for the formation of 3→3 cross-links in various bacterial species and shown that these enzymes are structurally unrelated to PBPs ([@bib19]). Gene deletion and complementation analyses have indicated that the chromosome of *E. coli* encodes five L,D-transpeptidases with distinct functions. Two paralogues form the DAP^3^→DAP^3^ peptidoglycan cross-links (YcbB and YnhG) ([@bib17]), whereas the three remaining paralogues anchor the Braun lipoprotein to peptidoglycan (YbiS, ErfK, and YcfS) ([@bib16]).

Here we show that the L,D-transpeptidase activity of YcbB, but not that of YnhG, is able to replace the D,D-transpeptidase activity of all five class A and B PBPs of *E. coli*, leading to β-lactam resistance. We have also identified the various factors required for bypass of the PBPs by YcbB, which include the enzyme partners of the L,D-transpeptidase for peptidoglycan polymerization and upregulation of the (p)ppGpp alarmone synthesis.

Results {#s2}
=======

YcbB-mediated β-lactam resistance {#s2-1}
---------------------------------

β-lactams of the penam and cephem classes, such as ampicillin and ceftriaxone, respectively, effectively inactivate D,D-transpeptidases belonging to the PBP family. In contrast, L,D-transpeptidases are slowly acylated by these drugs and the resulting acyl-enzymes are unstable ([@bib31]). This accounts for L,D-transpeptidase-mediated penam and cephem resistance since slow acylation combined with acyl-enzyme hydrolysis results in partial L,D-transpeptidase inhibition. In this study, resistance to ampicillin and ceftriaxone was used to assess the capacity of L,D-transpeptidases to bypass PBPs in *E. coli*. In order to control the level of production of the L,D-transpeptidase YcbB, the corresponding gene was cloned under the control of the IPTG-inducible *trc* promoter of the vector pTRCKm. The resulting plasmid, pJEH11(*ycbB*), was introduced into strain BW25113Δ4 (8), which does not harbor any of the remaining L,D-transpeptidase genes, *i.e. ynhG*, *ybiS*, *erfK*, and *ycfS*. Plasmid pJEH11(*ycbB*) did not confer ampicillin resistance to this host in the absence of IPTG or in media containing low concentrations of this inducer (up to 50 µM). Induction of *ycbB* expression with IPTG concentrations greater than 50 µM prevented bacterial growth, indicating that high-level production of the L,D-transpeptidase YcbB was toxic. Selection for ampicillin resistance (32 µg/ml) in the presence of IPTG (500 µM) yielded mutant M1, which was not inhibited by 500 µM IPTG and displayed IPTG-inducible resistance to ampicillin and ceftriaxone ([Figure 2](#fig2){ref-type="fig"}). Genetic analyses showed that mutant M1 harbors two mutations.10.7554/eLife.19469.003Figure 2.IPTG-inducible expression of β-lactam resistance in mutant M1(pJEH11-1).The diffusion assay was performed with disks containing 30 µg of ampicillin (AM), 30 µg of ceftriaxone (CRO), or 10 µg of IPTG.**DOI:** [http://dx.doi.org/10.7554/eLife.19469.003](10.7554/eLife.19469.003)

To identify the first mutation, the plasmid was extracted from mutant M1 and introduced into the parental strain *E. coli* BW25113Δ4. Toxicity associated with *ycbB* induction was not observed and the plasmid did not confer ampicillin resistance. Sequencing revealed a mutation located in the vector-born *lacI* gene resulting in an Arg^127^Leu substitution in the inducer binding site. Thus, the plasmid-borne mutation abolished YcbB toxicity by decreasing the level of *ycbB* transcription in inducing conditions. The toxicity associated with high-level production of YcbB may be linked to the putative membrane anchor of the protein as demonstrated for PBP2 in *E. coli* ([@bib15]).

To identify the second mutation, a cured derivative of M1 was obtained by spontaneous loss of the derivative of pJEH11(*ycbB*) harboring the *lacI* mutation, which was designated pJEH11-1(*ycbB*). The resulting strain, designated M1~cured~, was susceptible to ampicillin and attempts to select ampicillin-resistant derivatives of that strain were negative (survivor frequency \< 10^--9^). Introduction of pJEH11-1(*ycbB*) into M1~cured~ restored ampicillin resistance. These results indicate that a chromosomal mutation is required for ampicillin resistance in addition to the expression of the plasmid copy of *ycbB.*

Testing a large panel of β-lactams using the disk diffusion assay indicated that IPTG-inducible expression of *ycbB*, in combination with the chromosomal mutation, confers broad-spectrum resistance to β-lactams, with the exception of carbapenems ([Table 1](#tbl1){ref-type="table"}). This conclusion is supported by the phenotypes of the parental strain BW25113Δ4, mutant M1, a derivative of this mutant (M1~cured~) devoid of *ycbB* following the spontaneous loss of plasmid pJEH11-1(*ycbB*), and of a derivative of M1~cured~ expressing *ycbB* following introduction of the plasmid pJEH12(*ycbB*), which is identical to pJEH11-1, except for the origin of replication and the selectable resistance marker.10.7554/eLife.19469.004Table 1.Susceptibility of *E*. *coli* strains determined by the disk diffusion assay.**DOI:** [http://dx.doi.org/10.7554/eLife.19469.004](10.7554/eLife.19469.004)AntibioticLoad (µg)BW25113Diameter of inhibition zones (mm) for the indicated strains\*BW25113Δ4M1IPTG 50 µMM1~cured~M1~cured~pJEH12(*ycbB*)M1~cured~pJEH12(*ycbB*)IPTG 50 µMAmoxicillin25232413282816Ampicillin102121ND^§^2726NDAmox+Clav^†^20+10202313273011Piperacillin752928ND3636NDPip+Tazo^‡^75+102930ND3737NDTicarcillin752627ND3731NDMecillinam101722NDNDNDNDAztreonam303336ND4947NDCefalotin301618ND2323NDCefoxitin30202529303030Cefotetan30303125414127Ceftazidime302930ND39379Cefotaxime303336ND44449Cefixime102830ND3738NDCefpirome303133ND41419Cefoperazone302728ND4140NDMoxalactam30313215434017Ceftriaxone30333215424218**Carbapenems** Doripenem10313432383738 Meropenem10303435404134 Imipenem10263035252728 Ertapenem10303537494737[^1][^2][^3][^4]

Expression of *ynhG* in mutant M1 does not enable emergence of ampicillin resistance {#s2-2}
------------------------------------------------------------------------------------

Deletion of both *ynhG* and *ycbB* is required to suppress the in vivo formation of 3→3 cross-links ([@bib17]). Since these results strongly suggest that both genes encode peptidoglycan L,D-transpeptidases, we investigated whether YnhG was able to bypass PBPs, as shown for YcbB. To address this question, the gene *ynhG* was cloned under the control of the *trc* promoter of pTRCKm, and the resulting plasmid was introduced into M1~cured~ and BW25113Δ4. The resulting plasmid did not confer ampicillin resistance in either host. Ampicillin-resistant mutants were not obtained using various concentrations of IPTG and ampicillin (frequency \< 10^--9^). These results indicate that bypass of the D,D-transpeptidase activity of the PBPs was only possible with YcbB.

Contribution of YcbB to the formation of peptidoglycan cross-links {#s2-3}
------------------------------------------------------------------

The respective contributions of PBPs and YcbB to peptidoglycan polymerization were assessed by determining the relative proportions of 4→3 and 3→3 cross-links in mutant M1 ([Figure 3](#fig3){ref-type="fig"}). The sequence of the cross-links was determined by tandem mass spectrometry analysis of purified peptidoglycan fragments ([Figure 4](#fig4){ref-type="fig"} and data not shown). In the presence of ampicillin, the D,D-transpeptidase activity of the PBPs was inhibited, and all cross-links were of the 3→3 type. These results indicate that YcbB is sufficient for peptidoglycan cross-linking in the absence of the D,D-transpeptidase activity of the PBPs.10.7554/eLife.19469.005Figure 3.Peptidoglycan composition of mutant M1 grown in presence of ampicillin (16 µg/ml).(**A**) *rp*HPLC profile of disaccharide-peptides. Absorbance was recorded at 210 nm (mAU, absorbance units x 10^3^). (**B**) Identification of disaccharide-peptides by mass spectrometry. The relative abundance of peptidoglycan fragments was estimated as the percentage of the total integrated area. The observed and calculated monoisotopic mass of muropeptides is indicated in Da. GM, GlcNAc-MurNAc; ^anh^, anhydro; ^R^, reduced; Tri, tripeptide L-Ala-γ-D-Glu-DAP (DAP, diaminopimelic acid); Tetra, tetrapeptide L-Ala-γ-D-Glu-DAP-D-Ala; Tri-Gly, tetrapeptide L-Ala-γ-D-Glu-DAP-Gly; Penta, pentapeptide L-Ala-γ-D-Glu-DAP-D-Ala-D-Ala; 3→3, cross-link generated by L,D-transpeptidation.**DOI:** [http://dx.doi.org/10.7554/eLife.19469.005](10.7554/eLife.19469.005)10.7554/eLife.19469.006Figure 4.Sequencing of the peptidoglycan cross-link of lactoyl-peptides by tandem mass spectrometry.The figure illustrates the capacity of the method to discriminate isomers containing 3→3 (**A**) and 4→3 (**B**) cross-links. Fragments specific of each isomer are shown in red. L, D-Lac; A, L-Ala or D-Ala; a, C-terminal D-Ala; E, D-Glu; DAP, diaminopimelic acid. All dimers present in peptidoglycan preparations from mutant M1 were identified by this method.**DOI:** [http://dx.doi.org/10.7554/eLife.19469.006](10.7554/eLife.19469.006)

L,D-transpeptidase activity of YcbB {#s2-4}
-----------------------------------

A soluble fragment of YcbB, devoid of the putative membrane anchor of the protein, was produced in *E. coli*, purified, and assayed for in vitro formation of peptidoglycan cross-links. Incubation of YcbB with a disaccharide-tetrapeptide prepared from the peptidoglycan of *E. coli* resulted in the formation of a peptidoglycan dimer containing a DAP^3^→DAP^3^ cross-link ([Figures 5](#fig5){ref-type="fig"} and [6A](#fig6){ref-type="fig"}). Purified YcbB also displayed L,D-carboxypeptidase activity as the enzyme removed the C-terminal residue (D-Ala^4^) from the tetrapeptide stem ([Figures 5](#fig5){ref-type="fig"} and [6A](#fig6){ref-type="fig"}). These results confirm that YcbB is a *bona fide* L,D-transpeptidase, which directly accounts for the synthesis of DAP^3^→DAP^3^ cross-links in mutant M1.10.7554/eLife.19469.007Figure 5.Mass spectrometry analysis of the products of the reactions catalyzed in vitro by YcbB.(**A**) Disaccharide-tetrapeptide used as the substrate. The muropeptide GlcNAc-MurNAc-L-Ala^1^-γ-D-Glu^2^-DAP^3^-D-Ala^4^ (Tetra) was purified from the *E. coli* cell wall peptidoglycan. The peak at *m*/*z* 942.4250 \[M+H\]^1+^ corresponds to an observed mass (M~obs~) of 941.42 Da in agreement with the calculated mass (M~cal~) of 941.41 Da. (**B**) Reaction products. YcbB (10 µM) was incubated with the disaccharide-tetrapeptide (30 µM) for 2 hr at 37°C revealing the formation of (i) the tripeptide GlcNAc-MurNAc-L-Ala^1^-γ-D-Glu^2^-DAP^3^ (Tri; M~obs~ = 870.40 Da; M~cal~ = 870.37 Da) by the L,D-carboxypeptidase activity of YcbB; (ii) the peptidoglycan dimer bis-disaccharide-Tri-Tetra (M~obs~ = 1793.80 Da; M~cal~ = 1793.77 Da) by the L,D-transpeptidase activity of YcbB; and the peptidoglycan dimer bis-disaccharide-Tri-Tri (M~obs~ = 1722.78 Da; M~cal~ = 1722.73 Da) by the L,D-transpeptidase and L,D-carboxypeptidase activities of YcbB.**DOI:** [http://dx.doi.org/10.7554/eLife.19469.007](10.7554/eLife.19469.007)10.7554/eLife.19469.008Figure 6.Reactions catalyzed by the L,D-transpeptidase, YcbB.(**A**) In vitro cross-linking assay. Incubation of YcbB with the reduced disaccharide GlcNAc-MurNAc-tetrapeptide resulted in the formation of a dimer containing a 3→3 cross-link (L,D-transpeptidase activity). YcbB also hydrolyzed the C-terminal D-Ala^4^ residue of tetrapeptide stems (L,D-carboxypeptidase activity). The muropeptides were determined by mass spectrometry. The observed (M~obs~) and calculated (M~cal~) monoisotopic masses are indicated in Daltons. The pentapeptide GlcNAc-MurNAc-L-Ala^1^-γ-D-Glu^2^-DAP^3^-D-Ala^4^-D-Ala^5^ was not a substrate of YcbB. The reaction used to label peptidoglycan with a fluorescent derivative of D-Ala (NADA) is indicated. (**B**) Acylation of YcbB by β-lactams. Incubation of YcbB with two carbapenems, *i.e.* meropenem and imipenem, led to the acyl-enzymes shown, which were stable. In contrast, the acyl-enzyme formed with ceftriaxone was unstable, accounting for resistance of mutant M1 to this cephalosporin. The observed (M~obs~) and calculated (M~cal~) average masses are indicated in Daltons. No adduct was observed with amoxicillin.**DOI:** [http://dx.doi.org/10.7554/eLife.19469.008](10.7554/eLife.19469.008)

Inactivation of YcbB by β-lactams {#s2-5}
---------------------------------

Incubation of YcbB with representatives of the β-lactams belonging to the carbapenem class, *i.e.* meropenem and imipenem, led to full and irreversible acylation of the protein, as detected by mass spectrometry ([Figures 6B](#fig6){ref-type="fig"} and [7](#fig7){ref-type="fig"}). In contrast, adducts resulting from acylation of YcbB by β-lactams of the penam and cephem classes were prone to hydrolysis (data no shown), as previously described for Ldt~fm~ from *E. faecium* ([@bib31]). Thus, the inhibition profile of purified YcbB accounts for broad-spectrum resistance to all β-lactams except carbapenems ([Table 1](#tbl1){ref-type="table"}).10.7554/eLife.19469.009Figure 7.Mass spectrometry analyses of the adducts resulting from acylation of YcbB by the β-lactams imipenem, meropenem, and ceftriaxone.YcbB (10 µM) was incubated with β-lactams (100 µM) for 1 hr at 37°C. The peaks correspond to the \[M+71H\]^71+^ and \[M+72H\]^72+^ ions. The observed (M~obs~) and calculated (M~cal~) masses are indicated. Acylenzymes formed with ceftriaxone (a cephem) were detected although they were slowly hydrolyzed, as previously described for Ldt~fm~ from *E. faecium* ([@bib31]). Acylenzymes formed with ampicillin (a penam) were not detected by mass spectrometry.**DOI:** [http://dx.doi.org/10.7554/eLife.19469.009](10.7554/eLife.19469.009)

Identification of the class C PBP partner of YcbB {#s2-6}
-------------------------------------------------

Purified YcbB used as the acyl donor a disaccharide-tetrapeptide ending in D-Ala^4^, but not a disaccharide-pentapeptide ending in D-Ala^4^-D-Ala^5^ ([Figure 6A](#fig6){ref-type="fig"}). We therefore investigated low-molecular-weight class C PBPs to identify the D,D-carboxypeptidase that generates the substrate of YcbB by cleavage of the D-Ala^4^-D-Ala^5^ peptide bond of pentapeptide stems. We reasoned that selection for YcbB-mediated ampicillin resistance could be used to determine whether a host strain produces the D,D-carboxypeptidase partner of YcbB for peptidoglycan polymerization. Note that partner refers in the context of this study to an enzyme that is essential for peptidoglycan polymerization in conditions where YcbB is the sole functional transpeptidase without implying that a physical contact between YcbB and that protein exists or is essential for enzyme activity. We therefore introduced plasmid pJEH12(*ycbB*) into the mutant from the Keio collection that harbors a kanamycin-resistance cassette in place of *dacA* encoding class C PBP5 (12). Plating the resulting strain on agar containing ceftriaxone (32 µg/ml) and IPTG (50 µM) led to no survivors (frequency \<10^--9^), unless a plasmid copy of *dacA* was provided *in trans* (9 × 10^--6^) ([Table 2](#tbl2){ref-type="table"}). Thus, the D,D-carboxypeptidase PBP5 was essential for YcbB-mediated β-lactam resistance. In contrast, independent deletions of *dacB, dacC,* and *dacD* encoding PBP4, PBP6, and PBP6b, respectively, had no impact on the frequency of selection of ceftriaxone-resistant mutants ([Table 2](#tbl2){ref-type="table"}). Further analyses were performed with strain CS801-4 (13), which was obtained by deletions of *dacA, dacB, dacC, dacD, mrcA*, *ampH*, and *ampC* ([Table 3](#tbl3){ref-type="table"}). In this host, plasmids pJEH12(*ycbB*) and p*Trc*99AΩ*dacA* were both required for selection of ceftriaxone-resistant mutants. These results indicate that the D,D-carboxypeptidase activity of PBP5 is necessary and sufficient to generate the essential tetrapeptide-containing substrate of YcbB. It is of note that PBP5 is only inhibited by high concentrations of β-lactams ([@bib5]). This accounts for the proposed participation of PBP5 in peptidoglycan synthesis in the presence of β-lactams. This also accounts for the residual activity of cefoxitin ([Table 1](#tbl1){ref-type="table"}, inhibition zone of 30 mm) since this cephalosporin displays moderate activity against PBP5 (14).10.7554/eLife.19469.010Table 2.Selection of β-lactam-resistant derivatives of *E*. *coli* BW25113 harboring various plasmids.**DOI:** [http://dx.doi.org/10.7554/eLife.19469.010](10.7554/eLife.19469.010)**Deletion^\*^Plasmid 1Plasmid 2Frequency x 10^9†^**NonepACYC184p*Trc*99A\<1NonepJEH12(*ycbB*)none3200dacApJEH12(*ycbB*)none\<1dacApJEH12(*ycbB*)p*Trc*99AΩ*dacA*9100dacBpJEH12(*ycbB*)none13,000dacCpJEH12(*ycbB*)none9000dacDpJEH12(*ycbB*)none9100mrcBpJEH12(*ycbB*)p*Trc*99A\<1mrcBpJEH12(*ycbB*)p*Trc*99AΩ*mrcB*6400mrcBpJEH12(*ycbB*)p*Trc*99AΩ*mrcB* TG (E^233^M) ^‡^\<1mrcBpJEH12(*ycbB*)p*Trc*99AΩ*mrcB* TP (S^510^A)^§^1700mrcApJEH12(*ycbB*)none1600pbpCpJEH12(*ycbB*)none2700mgtApJEH12(*ycbB*)none2700lpoApJEH12(*ycbB*)none5000lpoBpJEH12(*ycbB*)none\<1[^5][^6][^7][^8]10.7554/eLife.19469.011Table 3.Selection of β-lactam-resistant derivatives of *E*. *coli* CS801-4 harboring various plasmids.**DOI:** [http://dx.doi.org/10.7554/eLife.19469.011](10.7554/eLife.19469.011)**Plasmid 1Plasmid 2Frequency x 10^9^**pACYC184p*Trc*99A\<1pJEH12(*ycbB*)None\<1pJEH12(*ycbB*)p*Trc*99A\<1nonep*Trc*99AΩ*dacA*\<1pJEH12(*ycbB*)p*Trc*99AΩ*dacA*5900[^9]

Identification of the glycosyltransferase partner of YcbB {#s2-7}
---------------------------------------------------------

Since the L,D-transpeptidase YcbB does not harbor a glycosyltransferase-related domain, peptidoglycan polymerization in the presence of ampicillin is predicted to require cooperation between the L,D-transpeptidase activity of YcbB and the glycosyltransferase activity of housekeeping enzymes. *E. coli* produces four candidate enzymes for the latter function, including three class A PBPs (PBP1a, PBP1b, and PBP1c) and a monofunctional glycosyltransferase (MgtA) ([Figure 1A](#fig1){ref-type="fig"}) encoded by the genes *mrcA*, *mrcB*, *pbpC*, and *mgtA*, respectively ([@bib24]). To determine which of these four enzymes cooperate with YcbB, plasmid pJEH12(*ycbB*) was introduced into four mutants of the Keio collection harboring a kanamycin-resistance gene cassette in place of each of the four glycosyltransferase genes. Ceftriaxone-resistant mutants were obtained with the *mrcA*, *pbpC*, and *mgtA* mutants, but not with the *mrcB* mutant, indicating that PBP1b is an essential partner of YcbB for peptidoglycan polymerization in the presence of β-lactams.

PBP1b is a bifunctional class A PBP containing transpeptidase and glycosyltransferase modules. To assess the role of the transpeptidase activity of PBP1b, the *mrcB* gene was introduced into plasmid p*Trc*99A, and the transpeptidase module was inactivated by the substitution S^510^A ([@bib28]). It has been previously shown that PBP1b harboring this substitution is able to catalyze in vitro the polymerization of lipid II into glycan strands in the absence of TPase activity ([@bib28]; [@bib10]). The derivatives of p*Trc*99A encoding wild-type PBP1b and PBP1b S^510^A were introduced into the strain BW25113Δ*mrcB* harboring pJEH12(*ycbB*). Selection of ceftriaxone-resistant mutants was obtained in both cases. Thus, the glycosyltransferase activity of PBP1b, but not its D,D-transpeptidase activity, is required for YcbB-mediated β-lactam resistance. We also tested PBP1b harboring the E^233^M substitution inactivating the glycosyltransferase domain of the protein using the same approach. As expected, ceftriaxone-resistant mutants were not obtained with derivative of BW25113Δ*mrcB* producing YcbB and PBP1b E^233^M. The limitation of the latter observation is that no or significantly reduced transpeptidase activity is observed when the glycosyltransferase of *E. coli* class A PBPs is not functional, although the latter enzymes still bind β-lactam antibiotics indicating a properly folded transpeptidase domain ([@bib28]; [@bib10]; [@bib3]; [@bib2]; [@bib7]). PBP1b E^233^M may therefore be deficient in both transpeptidase and transglycosylase activities.

To determine whether PBP1b was sufficient for resistance, we constructed by serial deletions a derivative of BW25113 lacking chromosomal copies of *mrcA*, *mrcB*, *pbpC*, and *mgtA.* This mutant, designated BW25113Δ4GT/pMAK705Ω*mrcB*, was viable at 30°C owing to the expression of a plasmid copy of *mrcB* harbored by the vector pMAK705, which is thermosensitive for replication. Mutants displaying IPTG-inducible ceftriaxone resistance were obtained by plating BW25113Δ4GT harboring pMAK705Ω*mrcB* and pJEH12(*ycbB*) at 30°C on agar containing ceftriaxone (32 µg/ml) and IPTG (50 µM) (frequency of survivors of 5 × 10^--7^). Mutants were also obtained at 37°C if pMAK705Ω*mrcB* was replaced by p*Trc*99AΩ*mrcB*, which is not thermosensitive for replication. Together, these results indicate that the glycosyltransferase activity of PBP1b is necessary and sufficient for glycan-chain elongation when YcbB is the only functional cross-linking enzyme.

The outer membrane lipoproteins LpoA and LpoB have been shown to be essential for the activity of class A PBP1a and PBP1b, respectively ([@bib22]; [@bib33]). As expected, ampicillin-resistant mutants were only obtained with the *lpoA* mutant ([Table 2](#tbl2){ref-type="table"}), indicating that LpoB is essential for the participation of PBP1b in glycan-chain elongation in the context of peptidoglycan cross-linking by YcbB.

Bypass of the D,D-transpeptidase activity of class B PBPs by YcbB {#s2-8}
-----------------------------------------------------------------

*E. coli* produces two class B PBPs, PBP2 and PBP3, which are essential and specifically inhibited by mecillinam ([@bib27]; [@bib35]) and aztreonam ([@bib12]), respectively. In the presence of IPTG, mutant M1 was resistant to mecillinam and aztreonam, indicating that inhibition of the D,D-transpeptidase module of the class B PBPs did not impair YcbB-mediated ampicillin resistance ([Table 1](#tbl1){ref-type="table"} and data not shown). Surprisingly, M1 was resistant to mecillinam in the absence of IPTG. M1~cured~ was also resistant to mecillinam, indicating that resistance to this antibiotic was mediated by a chromosomal mutation independently from YcbB production ([Table 1](#tbl1){ref-type="table"}). This observation raised the possibility that the same mutation might be responsible both for mecillinam resistance in the absence of YcbB in M1~cured~ and for broad-spectrum resistance to penams and cephems in M1 following the induction of the plasmid copy of *ycbB* by IPTG. To test this hypothesis, derivatives of strain BW25113/pJEH12(*ycbB*) were selected on media containing mecillinam alone (50 µg/ml) or ampicillin (32 µg/ml) and IPTG (50 µM). Independent mutants obtained on each selective medium were analyzed for expression of β-lactam resistance. Four of the seven mutants selected on mecillinam remained susceptible to ampicillin both in the presence or absence of IPTG. The three remaining mecillinam-resistant mutants (M2, M3, and M4) displayed IPTG-inducible ampicillin resistance, as did mutant M1. All six mutants selected on ampicillin-and-IPTG-containing media (M5 to M10) were resistant to mecillinam in the absence of IPTG and, additionally, resistant to ampicillin in its presence (as was M1). These results indicate that acquisition of a mutation conferring mecillinam resistance is necessary and sufficient for YcbB-mediated ampicillin resistance. In contrast, only a portion of the mutations conferring mecillinam resistance enabled YcbB-mediated ampicillin resistance.

Identification of chromosomal mutations essential for YcbB-mediated ampicillin resistance {#s2-9}
-----------------------------------------------------------------------------------------

Whole genome sequencing revealed that mutants M1 to M7 each harbored a single mutation ([Table 4](#tbl4){ref-type="table"}). This observation confirms that a single mutation is responsible for mecillinam resistance in the absence of YcbB and for YcbB-mediated broad-spectrum β-lactam resistance upon *ycbB* induction by IPTG. Mutant M1 harbored a 13-bp deletion located in an untranslated region upstream from the isoleucine-tRNA synthetase (IleRS) gene. The remaining mutants (M2 to M7) harbored missense mutations in genes encoding ArgRS, ThrRS, GluRS, and AspRS, with two distinct substitutions for the latter two enzymes.10.7554/eLife.19469.012Table 4.Mutations detected in M1 to M7.**DOI:** [http://dx.doi.org/10.7554/eLife.19469.012](10.7554/eLife.19469.012)**MutantSelectionPositionMutationImpact**M1Ap22,373Δ13-nt^\*^IleRS translationM2Me1,960,069T→CI^3^T in ArgRSM3Me1,801,022A→CS^517^A in ThrRSM4Ap2,520,555G→TR^40^S in GluRSM5Ap2,520,540C→TD^45^N in GluRSM6Ap1,948,853G→TT^557^N in AspRSM7Ap1,950,015G→AP^170^S in AspRS[^10][^11]

The deletion present in M1 most probably impairs translation of IleRS since it ends 5 nucleotides upstream from the ATG codon and includes the ribosome binding site. Thus, the mutation present in M1 impaired aminoacylation of tRNA^Ile^, a defect known to result in activation of (p)ppGpp synthesis by RelA in response to ribosomal stalling, following occupancy of the ribosome acceptor site by uncharged tRNAs ([@bib13]). The same conclusion is also likely to apply to missense mutations in the aminoacyl-tRNA synthetase genes of mutants M2 to M7, although we cannot exclude the possibility that the corresponding amino acid substitutions altered other properties of the proteins.

Production of (p)ppGpp triggers expression of YcbB-mediated ampicillin resistance {#s2-10}
---------------------------------------------------------------------------------

In order to modulate the level of synthesis of (p)ppGpp, a fragment of *relA* encoding the first 455 residues of the protein was cloned under the control of the arabinose-inducible promoter of vector pBAD33. The truncated protein encoded by the resulting plasmid, pBAD33Ω*relA* 1--455, is devoid of the C-terminal ribosome binding module and constitutively synthesizes (p)ppGpp ([@bib25]). The latter plasmid and a compatible plasmid coding for IPTG-inducible synthesis of YcbB, pKT2(*ycbB*), were introduced into a derivative of *E. coli*, BW25113, lacking the chromosomal copy of *relA*. In the absence of both inducers, the resulting strain was susceptible to β-lactams, as was the parental strain BW25113 ([Figure 8A](#fig8){ref-type="fig"}). Induction of YcbB synthesis by IPTG had no impact on the activity of β-lactams ([Figure 8B](#fig8){ref-type="fig"}). Induction of RelA 1--455 synthesis by arabinose led to expression of resistance to mecillinam, but not to other β-lactams ([Figure 8C](#fig8){ref-type="fig"}). Induction of both RelA 1--455 and YcbB recapitulated the phenotype of mutant M1 ([Figure 8D](#fig8){ref-type="fig"}). These results indicate that YcbB production and increased (p)ppGpp synthesis are both required for bypass of the D,D-transpeptidase activity of PBPs and broad-spectrum β-lactam resistance. Production of (p)ppGpp by RelA 1--455 recapitulates the phenotype conferred by mutations in the aminoacyl-tRNA synthetase genes of mutants M1 to M7, in agreement with their proposed role in the activation of (p)ppGpp synthesis by RelA in response to binding of uncharged tRNAs to the ribosome acceptor site.10.7554/eLife.19469.013Figure 8.Impact of induction of RelA 1--455 and YcbB synthesis on the activity of β-lactams.Antibiograms using the disk diffusion assay were performed on BHI agar (**A**) supplemented with 50 µM IPTG (**B**), 1% arabinose (**C**) or both inducers (**D**), to induce expression of *ycbB* and *relA* 1--455 encoded by compatible plasmids pKT2 and pKT8, respectively. Disks were loaded with 10 µg of mecillinam (1), 10 µg of ampicillin (2), 30 µg of ceftriaxone (3), 30 µg of tetracycline (4), 10 µg of imipenem (5), or 30 µg of chloramphenicol (6). Plates were inoculated with BW25113Δ*relA* harboring plasmids pKT8(*relA*) and pKT2(*ycbB*).**DOI:** [http://dx.doi.org/10.7554/eLife.19469.013](10.7554/eLife.19469.013)

Localization of YcbB activity {#s2-11}
-----------------------------

L,D-transpeptidases catalyze the exchange of D-Ala^4^ at the C-terminus of tetrapeptide stems by various D-amino acids ([@bib18]). The first step in this reaction involves nucleophilic attack of the carbonyl of DAP^3^ by the catalytic Cys of the enzyme, leading to the release of D-Ala^4^ and formation of a thioester bond ([Figure 6A](#fig6){ref-type="fig"}). In the second step, the resulting acyl-enzyme is attacked by the D-amino acid, leading to the formation of a DAP-D-amino acid peptide bond. We used a fluorescent derivative of D-Ala (NADA) ([@bib14]) to localize YcbB activity in live bacteria. As shown in [Figure 9](#fig9){ref-type="fig"}, intense labeling was detected at mid-cell indicating that YcbB and its tetrapeptide substrate are co-localized in the septum. As controls, we also showed that labeling was inhibited by meropenem, which inactivates YcbB and PBPs, but not by ampicillin, which only inactivates PBPs.10.7554/eLife.19469.014Figure 9.Localization of YcbB activity based on labeling of peptidoglycan with a fluorescent derivative of D-Ala (NADA).Mutant M1 was grown in the absence or in the presence of 50 µM IPTG to induce *ycbB* expression. Prior to labeling with NADA, bacteria were incubated with ampicillin, which inhibits PBPs but not YcbB, or meropenem, which inhibits all transpeptidases. The graphics in the lower panel correspond to the surface plot within the yellow rectangle.**DOI:** [http://dx.doi.org/10.7554/eLife.19469.014](10.7554/eLife.19469.014)

Discussion {#s3}
==========

*E. coli* is known to resist β-lactams through a combination of drug inactivation by β-lactamases and reduced access of the drugs to their targets following activation of efflux pumps and modification of outer membrane porins. Here we show that *E. coli* can also resist β-lactams through bypass of the D,D-transpeptidase activity of high-molecular-weight PBPs. The resistance mechanism required production of the L,D-transpeptidase YcbB, which was purified and shown to catalyze the formation of peptidoglycan cross-links in vitro ([Figure 6A](#fig6){ref-type="fig"}) and to be inactivated only by carbapenems ([Figure 6B](#fig6){ref-type="fig"}), accounting for broad-spectrum resistance to other classes of β-lactams ([Table 1](#tbl1){ref-type="table"}). The bypass mechanism involves substantial modification of the set of enzymes required for peptidoglycan polymerization. In wild-type strains, lateral expansion of the peptidoglycan network and the formation of the septum involve two protein complexes, the elongasome and the divisome, respectively, which integrate distinct sets of peptidoglycan polymerases with partially overlapping functions ([@bib8]) ([Figure 1](#fig1){ref-type="fig"}). In contrast, the L,D-transpeptidase activity of YcbB is sufficient for peptidoglycan cross-linking in mutant M1. This conclusion is based on the exclusive detection of DAP^3^→DAP^3^ cross-links in the peptidoglycan of M1 grown in the presence of ampicillin ([Figures 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}) and on mutagenic or chemical invalidation of the transpeptidase module of class-A or -B PBPs ([Table 2](#tbl2){ref-type="table"} and [Table 1](#tbl1){ref-type="table"}). In wild-type strains, glycan chains are polymerized by either PBP1a or PBP1b, although the former is preferentially associated with the elongasome and the latter with the divisome ([@bib8]). In contrast, PBP1b, together with its cognate lipoprotein LpoB, are both essential and sufficient for peptidoglycan polymerization in mutant M1 exposed to ampicillin. Peptidoglycan labeling with a fluorescent D-amino acid indicated that YcbB activity is preferentially located in the septum, as is its PBP1b partner ([Figure 9](#fig9){ref-type="fig"}). The cross-linking and glycosyltransferase activities of YcbB and PBP1b were nonetheless sufficient for lateral extension of the peptidoglycan network since bacterial cells retained a rod shape in the presence of ampicillin. This observation indicates that the cross-linking activity of high-molecular-weight PBPs is not indispensable to the maintenance of cell shape in *E. coli*. Together, our data identified a minimum set of enzyme activities that are necessary and sufficient for peptidoglycan polymerization in the presence of β-lactams ([Figure 10](#fig10){ref-type="fig"}). This set comprises the L,D-transpeptidase activity of YcbB, the glycosyltransferase activity of PBP1b, and the D,D-carboxypeptidase activity of PBP5, which provides the essential tetrapeptide substrate of YcbB. Bypass of the D,D-transpeptidase activity of PBPs by YcbB is potentially useful to explore the function of members of the polymerization complexes. For example, the fact that LpoB remains essential in the L,D-transpeptidation context indicates that it directly stimulates the glycosyltransferase activity of PBP1b, as indicated in a recent study ([@bib21]).10.7554/eLife.19469.015Figure 10.Peptidoglycan polymerization in mutant M1.The lipid intermediate II (Lipid II) consists in the disaccharide-pentapeptide subunit linked to the undecaprenyl lipid transporter (C~55~) by a pyrophosphate bond. *N*-acetylglucosamine linked to *N*-acetylmuramic acid (MurNAc) by a β1→4 bond is represented by light and dark blue hexagons, respectively. The pentapeptide stem is linked to the D-lactoyl group of MurNAc and assembled by the sequential addition of L-Ala (white circle), D-Glu (grey circle), *meso*-diamopimelic acid (DAP; black circle), and the dipeptide D-Ala-D-Ala (orange circles). Following translocation through the cytoplasmic membrane, the subunit is polymerized by the glycosyltransferase (GT) activity of PBP1b, which requires binding of LpoB to its UBH2 domain ([@bib35]). The transpeptidase (TP) activity of PBP1b and other PBPs is bypassed by the TP activity of YcbB that forms 3→3 cross-links (arrows) connecting DAP residues at the 3rd position of stem peptides. The donor substrate of YcbB is generated by the D,D-carboxypeptidase activity of PBP5.**DOI:** [http://dx.doi.org/10.7554/eLife.19469.015](10.7554/eLife.19469.015)

In addition to YcbB production, increased synthesis of the alarmone (p)ppGpp by RelA was required for broad-spectrum β-lactam resistance. This conclusion was drawn from the construction of strains that conditionally produce YcbB and a truncated form of RelA ([Figure 8](#fig8){ref-type="fig"}) ([Table 5](#tbl5){ref-type="table"}) and by an independent selection of mutants with impaired aminoacyl-tRNA synthetases ([Table 4](#tbl4){ref-type="table"}). Prior analyses also showed that PBP2 is not indispensable in *E. coli* when (p)ppGpp synthesis is increased, leading to mecillinam resistance ([@bib34]). Aside from mecillinam resistance, increased (p)ppGpp synthesis has also been shown to regulate growth rate and several different stress responses, including the response to exposure to antibiotics ([@bib13]). The latter leads to persistence, a response that involves production of rare cells within a bacterial population that remain susceptible but are not killed by the drugs, in the absence of acquisition of any mutation. In *E. coli*, tolerance to ampicillin mediated by increased (p)ppGpp synthesis leads to a 1000-fold reduction in bacterial killing. The bacterial cells are tolerant to numerous antibiotics, including non-β-lactams, such as ciprofloxacin, which acts on DNA topoisomerases ([@bib20]). The cascade triggered by elevated (p)ppGpp involves an increase in the intracellular concentration of polyphosphate via inhibition of the exopolyphosphatase PPX. In turn, elevated polyphosphate stimulates the protease activity of Lon, which degrades antitoxins, thereby activating the toxins that prevent bacterial killing through inhibition of translation and bacterial growth. This cascade is distinct from YcbB-mediated ampicillin resistance in several respects. Persistence emerges from stochastic events that render a limited number of bacterial cells transiently tolerant to multiple families of antibiotics, whereas YcbB in combination with elevated (p)ppGpp rendered the bulk of the population resistant only to β-lactams that did not inactivate the L,D-transpeptidase activity of YcbB ([Table 5](#tbl5){ref-type="table"}). In addition, plasmids pKT2(*ycbB*) and pKT8(*relA* 1--455) conferred ampicillin and ceftriaxone resistance to mutants from the Keio collection deficient in production of the Lon protease and the polyphosphate kinase PPK (data not shown) indicating that tolerance and resistance do not involve the same (p)ppGpp-regulated circuits.10.7554/eLife.19469.016Table 5.Minimal inhibitory concentration of β-lactams against *E*. *coli* strains harboring various plasmids^\*^.**DOI:** [http://dx.doi.org/10.7554/eLife.19469.016](10.7554/eLife.19469.016)β-lactamInducer^†^**Strains**BW25113BW25113pJEH12(*ycbB*)M1curedM1curedpJEH12(*ycbB*)BW25113pKT8(*relA*\')BW25113pKT8(*relA*\')pKT2(*ycbB*)BW25113ΔrelApKT8(*relA*\')**BW25113ΔrelApKT8(*relA*\')pKT2(*ycbB*)**AmpicillinNone88888484IPTG8881288484Ara88888884IPTG+Ara8881288648128CeftriaxoneNone0,050,050,050,050,050,050,050,05IPTG0,050,050,05320,050,050,050,05Ara0,050,050,050,050,050,10,050,05IPTG+Ara0,050,050,05320,05320,0532[^12][^13]

Materials and methods {#s4}
=====================

Strains, plasmids, and growth conditions {#s4-1}
----------------------------------------

All strains were derived from *E. coli* BW25113 (32), except strain CS801-4 (13), kindly provided by Kevin D. Young. Single-deletion strains were obtained from the Keio collection ([@bib1]), provided by the National BioRessource Project-*E.coli* at National Institute of Genetics (Shigen, Japan). Serial deletion of class A *pbp* genes was obtained by the one-step technique described by B. Wanner and K. Datsenko ([@bib6]) using the primers depicted in [Table 6.](#tbl6){ref-type="table"} Strains were grown in brain heart infusion broth or agar at 37°C unless otherwise specified.10.7554/eLife.19469.017Table 6.Oligonucleotides used in this study.**DOI:** [http://dx.doi.org/10.7554/eLife.19469.017](10.7554/eLife.19469.017)**OligonucleotideSequence**PBP1b-inact1`GAAGAACAGAAAATCGGGCTTTTGCGCCTGAATATTGCGGAGAAAAAGCCATATGAATATCCTCCTTAG`PBP1b-inact2`GTTATTTTACCGGATGGCAACTCGCCATCCGGTATTTCACGCTTAGATGGTGTAGGCTGGAGCTGCTTC`PBP1a-inact1`GCGCGTTTGTTTATAAACTGCCCAAATGAAACTAAATGGGAAATTTCCACATATGAATATCCTCCTTAG`PBP1a-inact2`CAAGTGCACTTTGTCAGCAAACTGAAAAGGCGCCGAAGCGCCTTTTTAAGTGTAGGCTGGAGCTGCTTC`PBPC-inact1`ATGCCTCGCTTGTTAACCAAACGCGGCTGCTGGATAACGTTGGCAGCCGCATATGAATATCCTCCTTAG`PBPC-inact2`CCGTCAAATGCAGGGTCACGTTGCGCCCGCGTTCAGTTAACGGTTCGCCGTGTAGGCTGGAGCTGCTTC`MGT-inact1`GCGGCATTGATAAGCTGGTTTCCCGCGTGCTGGTTCTGGCTGAATGAGTCATATGAATATCCTCCTTAG`MGT-inact2`TCGTGAGAGCAAAACGCTGGCCCTCACTTCGCGCGAAGCTTAATCCAGCGTGTAGGCTGGAGCTGCTTC`PBP1b-NcoI`AAAACCATGGCCGGGAATGACCGCGAGCCAATTGGACGC`PBP1b-SacI`GTTATGAGCTCGGATGGCAACTCGCCATCCGGTATTTCACGC`PBP1a-BspHI`TTCTCATGAAGTTCGTAAAGTATTTTTTGATCCTTGC`PBP1a-SacI`AGCCGGAGCTCGCGTTCACGCCGTATCCGGCATAAACAAGTGCAC`PMAK-PBP1b`CCAAGGATCCGTAAGGTTGGTTTTCTCCCTCTCCCTGTGGG`PBP1b-TG1`GCGACCATGGACCGTCATTTTTACGAGCATGATGGAATC`PBP1b-TG2`CGGTCCATGGTCGCCAGCAAAGTATCCACCAGCAAATCC`PBP1b-TP1`TCGATTGGCGCCCTTGCAAAACCAGCGACTTATCTGACGGC`PBP1b-TP2`TGCAAGGGCGCCAATCGAACGACGCGCCTGCATCGCACGG`RelA-XbaI`AATCTAGAAATCGATGGTACTTTTCTC`RelA-PstI`AACTGCAGCTACAGCTGGTAGGTGAACGGC`DacA-SacI`GGGAGCTCGGCATCTGATGTGTCAAT`DacA-BamHI`GGGGATCCTTAACCAAACCAGTGATGG`CDF-for`AACTGCAGTCATGAGCGGATACATAT`CDF-rev`AAATCGATATCTAGAGCGGTTCAGTAG`

Construction of plasmids expressing the L,D-transpeptidase gene *ycbB* {#s4-2}
----------------------------------------------------------------------

To avoid incompatibilities between antibiotic resistance markers and replication origins of the various plasmids used in this study, three plasmids encoding YcbB were constructed.

Construction of pJEH11(*ycbB*) was based on vector pTRCKm, a derivative of *pTrc*99A obtained by replacing the ampicillin-resistance gene by the kanamycin-resistance gene of pCR-Blunt (Invitrogen, Carlsbad, CA) (our laboratory collection). The gene *ycbB* of BW25113 carried by plasmid p*Trc*99AΩ*ycbB* ([@bib32]) was subcloned into the vector pTRCKm using restriction endonucleases NcoI and XbaI. The resulting plasmid was designated pJEH11(*ycbB*). A derivative of pJEH11(*ycbB*), designated pJEH11-1(*ycbB*), was obtained upon selection on p*Trc*99AΩ*ycbB* containing ampicillin and IPTG. Plasmid pJEH11-1(*ycbB*) carries a mutation in the *lacI* gene resulting in an Arg^127^Leu substitution in the inducer binding site of the LacI repressor.

To construct pJEH12(*ycbB*), the ApaI-XmnI fragment of pJEH11-1(*ycbB*) harboring *lacI* Arg^127^Leu, *ycbB*, and their respective promoters were cloned between the EcoRI and ScaI sites of pACYC184. For this construction, the EcoRI and ApaI protruding ends were blunted by treatment with the Klenow fragment of *E. coli* DNA polymerase I. The resulting plasmid, pJEH12(*ycbB*), contains the p15A replication origin, a tetracycline resistance marker, *lacI* Arg^127^Leu, and *ycbB* expressed under the control of the IPTG-inducible *trc* promoter.

To construct pKT2(*ycbB*), the origin of replication CDF was amplified by PCR with oligonucleotides CDF-for and CDF-rev ([Table 6](#tbl6){ref-type="table"}) from vector pCDFDuet-1 (Novagen). PstI and ClaI restriction sites were included at the 5' extremity of the forward and reverse primers, respectively. To replace the p15A replication origin of pJEH12(*ycbB*), the plasmid was digested with ClaI and PstI, and ligated to the CDF amplified PCR product digested with PstI and ClaI. The resulting plasmid, pKT2(*ycbB*), contains the CDF replication origin, a tetracycline resistance marker, *lacI* Arg^127^Leu, and *ycbB* expressed under the control of the *trc* promoter.

Peptidoglycan structure {#s4-3}
-----------------------

Peptidoglycan was extracted by the boiling SDS method and digested with muramidases ([@bib17]). The resulting muropeptides were reduced, separated by *rp*HPLC, collected, lyophilized, and identified by electrospray time-of flight mass spectrometry (Q-star Pulsar, Applied Biosystem) ([@bib17]). For tandem mass spectrometry, muropeptides were treated with ammonia to generate lactoyl-peptides following cleavage of the ether bond internal to *N*-acetyl-muramic acid (MurNAc) ([@bib17]). Lactoyl-peptides were separated by *rp*HPLC, collected, lyophilized, and identified by mass spectrometry. The sequence of the cross-links was determined by tandem mass spectrometry using N~2~ as the collision gaz (collision of 36--40 eV) ([@bib17]).

Purification of the L,D-transpeptidase, YcbB {#s4-4}
--------------------------------------------

The *ycbB* gene was amplified by PCR and cloned into pETMM82 (33) between the EcoRI and XhoI restriction sites. The fusion protein comprises the disulfide isomerase DsbC, a 6×His tag, a TEV protease cleavage site, and residues 30-616 of YcbB. The enzyme was produced in *E. coli* BL21(DE3) following induction by IPTG (0.5 mM) at 16°C for 19 hr. The fusion protein was purified from clarified lysates by nickel affinity chromatography in 25 mM Tris-HCl, 300 mM NaCl, pH 8.0 (buffer A). DsbC and the 6×His tag were removed by TEV protease digestion followed by nickel affinity chromatography. YcbB was further purified as a monomer by size-exclusion chromatography (Superdex 75 HiLoad 26/60, GE Healthcare) in buffer A.

Mass spectrometry analyses of YcbB acylation by β-lactams {#s4-5}
---------------------------------------------------------

The formation of drug-enzyme adducts was tested by incubating YcbB (10 µM) with β-lactams (100 µM) at 20°C in 100 mM sodium-phosphate buffer (pH 6.0) for 1 hr. Mass spectra were acquired in the positive mode (Qstar Pulsar I, Applied Biosystem) as previously described ([@bib31]).

In vitro peptidoglycan cross-linking assay {#s4-6}
------------------------------------------

The disaccharide-tetrapeptide GlcNAc-MurNAc-L-Ala^1^-γ-D-Glu^2^-DAP^3^-D-Ala^4^ was purified from the *E. coli* BW25113 cell-wall peptidoglycan (30 µM) and incubated with YcbB (10 µM) for 2 hr at 37°C in 25 mM Tris-HCl, 300 mM NaCl (pH 8.0). The reaction mixture was desalted (ZipTip C~18~; Millipore) and analyzed by mass spectrometry ([@bib30]).

Deletion of glycosyltransferase genes {#s4-7}
-------------------------------------

Inactivation of the genes *mrcA*, *mrcB, pbpC*, and *mgt* was performed by the Datsenko and Wanner technique ([@bib23]) with PCR products obtained by amplification of the kanamycin-resistance cassette with oligos PBP1a-inact1 and PBP1a-inact2 (*mrcA*), PBP1b-inact1 and PBP1b-inact2 (*mrcB*), PBPC-inact1 and PBPC-inact2 (*pbpC*), and MGT-inact1 and MGT-inact2 (*mgt*).

Construction of p*Trc*99A derivatives expressing the class A *mrcB* PBP gene {#s4-8}
----------------------------------------------------------------------------

Gene *mrcB* was amplified with oligonucleotides PBP1b-NcoI and PBP1b-SacI. The amplicon was digested with SacI and NcoI and cloned into p*Trc*99A digested by the same enzymes.

Construction of a pMAK705 derivative expressing *mrcB* {#s4-9}
------------------------------------------------------

pMAK705 is a replication thermosensitive plasmid (rep^ts^) ([@bib29]). *mrcB* was amplified with oligonucleotides PMAK-PBP1b and PBP1b-SacI, and the amplicon was digested with BamHI and SacI, and cloned into pMAK705 digested with the same enzymes.

Inactivation of the transpeptidase module of PBP1b {#s4-10}
--------------------------------------------------

A 5\' portion of the *mrcB* gene was amplified from plasmid p*Trc*99AΩ*mrcB* with oligonucleotides PBP1b-NcoI and PBP1b-TP2. The primer PBP1b-TP2 introduced a NarI site and replaced the codon specifying the catalytic residue Ser^510^ by an Ala codon. This amplicon, designated A1, was digested with NcoI and NarI. The remaining 3\' portion of the *mrcB* gene was amplified with primers PBP1b-SacI and PBP1b-TP1, which comprises a NarI site. The amplicon designated A2 was digested with NarI and SacI. The amplicons A1 and A2 were ligated to p*Trc*99A digested with NcoI and SacI.

Inactivation of the glycosyltransferase module of PBP1b {#s4-11}
-------------------------------------------------------

For inactivation of the glycosyltransferase module of PBP1b, a 5\' portion of the *mrcB* gene was amplified from plasmid p*Trc*99AΩ*mrcB* with primers PBP1b-NcoI and PBP1b-TG1. The primer PBP1b-TG1 introduced a NcoI site and replaced the codon specifying the catalytic residue Glu^233^ by a Met codon. The amplicon, designated B1 was digested with NcoI and HindIII. The remaining 3\' portion of the *mcrB* gene was amplified with primers PBP1b-SacI and PBP1b-TG2, which comprises a HindIII site. The amplicon, designated B2 was digested with HindIII and SacI. The amplicons B1 and B2 were ligated to p*Trc*99A digested with NcoI and SacI.

Construction of the plasmid pBAD33Ω*relA* 1--455 expressing a truncated form of RelA {#s4-12}
------------------------------------------------------------------------------------

A fragment of *relA* encoding residues 1--455 was amplified by PCR (primers RelA-XbaI and RelA-PstI) and cloned into vector pBAD33 using restriction endonucleases XbaI and PstI. The recombinant plasmid encodes a truncated version of RelA (residues 1 to 455), which is unable to bind to the ribosome and retains (p)ppGpp synthase activity ([@bib24]).

Selection of β-lactam resistant mutants {#s4-13}
---------------------------------------

*E. coli* strains were grown overnight in 10 ml of BHI broth at 37°C, concentrated by centrifugation, and *ca*. 10^9^ colony-forming units were plated on agar containing ampicillin (32 µg/ml) or ceftriaxone (32 µg/ml) and IPTG (50 µM). Colony-forming units were enumerated after 48 hr incubation at 37°C. To determine the frequency of survivors, cultures were also plated on BHI agar to enumerate bacteria present in the inoculum.

Assay for the identification of YcbB partners {#s4-14}
---------------------------------------------

In order to identify proteins essential for YcbB-mediated peptidoglycan cross-linking in the absence of the D,D-transpeptidase activity of PBPs, we expressed *ycbB* in *E. coli* mutants from the Keio collection, which were obtained by replacement of individual open-reading frames by a kanamycin-resistance gene cassette ([@bib8]). We hypothesized that insertion of the Km cassette in place of a gene encoding an essential partner of YcbB would produce a mutant unable to acquire ampicillin resistance despite production of the L,D-transpeptidase (frequency \< 10^--9^ on agar containing 32 µg/ml ampicillin or 32 µg/ml ceftriaxone, and 50 µM IPTG). For non-essential genes, mutants displaying IPTG-inducible expression of β-lactam resistance were obtained at a frequency ≥ 10^--6^).

Whole genome sequencing {#s4-15}
-----------------------

Genomic DNA was prepared with the Wizard Genomic DNA purification kit (Promega). Mutations were identified using the Illumina single reads sequencing technology. Library preparation was performed with Genomic DNA Sample Prep Kit v1. Nebulization was used to share genomic DNA, and fragments were blunt-ended, phosphorylated, and A-tailed prior to ligation of sequencing adapters. Fragments with an insert size of *ca.* 200 bp were gel-extracted and enriched with PCR (14 cycles) before library quantification and validation. Clusters were generated by hybridization of the library to the flow cell and bridge amplification. Single reads of 36 cycles were collected on a GAIIX (Illumina, San Diego, CA). The Illumina Analysis Pipeline (version 1.6) was used for image analysis, base calling, and error estimation. Raw sequence files were filtered using programs developed by N. Joly (Biology IT Center, Institut Pasteur, Paris). Quality-filtered trimmed reads (minimum 50 bases) were mapped on the genome sequence of *E. coli* BW25113 (ID: 2829859), and variant detection was performed with CLC Genomics Workbench version3 (CLC Bio, Denmark). Raw sequencing data have been deposited in the Dryad Digital Repository database ([@bib4]).

Probing of YcbB activity in live bacteria with a fluorescent D-amino acid {#s4-16}
-------------------------------------------------------------------------

M1~cured~ harboring pJEH12(*ycbB*), was grown in the absence or presence of 50 µM IPTG in lysogeny broth (LB) to an optical density at 600 nm of 0.3 at 37°C. The bacterial culture was further incubated with 16 µg/ml ampicillin or 1 µg/ml meropenem at 37°C for 30 and 15 min, respectively. A fluorescent derivative of D-Ala containing a 7-nitrobenzofurazan fluorophore (NADA; 1 mM) ([@bib14]) was added to the culture under constant shaking and incubation was continued for 150 s at 37°C. Cells were washed three times in LB (5000 rpm; 5 min), immobilized on 0.1 x LB containing 1% agarose, and incorporation of NADA was determined with a Nikon Eclipse T1 microscope (Nikon Plan Fluor × 100/1.30 Oil Ph3 DLL objective) coupled to an EMCCD camera (Hamamatsu Flash 4.0). Images were further analyzed by ImageJ (NIH).
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Factors essential for L,D-transpeptidase mediated peptidoglycan crosslinking and β-lactam resistance in *Escherichia coli*\" for consideration by *eLife*. Your article has been favorably evaluated by Wendy Garrett as the Senior Editor and three reviewers, including Jose Lemos (Reviewer \#3) and Michael S. Gilmore, who is a member of our Board of Reviewing Editors.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This is a generally well written and technically highly competent manuscript for which there would be a high level of enthusiasm if the issues below can be adequately addressed. It describes the conditions necessary to generate a complete, ampicillin-resistant cell wall by employing a previously identified L,D-transpeptidase activity mediated by YcbB, in conjunction with increased alarmone levels. The importance of this work is that peptidoglycan biosynthesis represents a complex activity that is uniquely microbial, which can be targeted by molecules that do not require translocation across the cytoplasmic membrane. The contribution of YcbB to generation of the unusual 3-3 crosslinks that ordinarily constitutes \~ 10% of the *E. coli* peptidoglycan was discovered by this group in 2008 ([@bib11]). The present work extends that to show that this activity, combined with an elevation in alarmone ppGpp, PBP1b and DacA expression, are sufficient for complete cell wall biosynthesis in a manner that is resistant to ampicillin inhibition. A main attraction for this theme is the problem of antibiotic resistance, and this pathway renders the cell ampicillin resistant in vitro.

Essential revisions:

A major limitation of the manuscript in its current form is that are some gaps in logic and omissions of critical data. For example, there is broad interest in the field in antibiotic resistance, and the central theme of this paper is the ampicillin-resistant generation of a complete cell wall. However, this reviewer is unfamiliar with that happening in nature, and as a result, most β-lactam related resistance is mediated by drug modifying enzymes and efflux -- is that the case? For the sake of a balanced perspective, the authors should discuss any evidence that this bypass occurs, or if not, why not?

In terms of leaps of logic in the experimentation that require further explanation:

1\) As it currently reads (subsection "YcbB-mediated β-lactam resistance", first paragraph), it appears that selection for both resistance to 500 μg/ml IPTG induction and resistance to 32 μg/ml ampicillin were performed simultaneously. Is this correct? If so, the rationale as well as rate of mutation should be better explained and documented, as this is central to the manuscript.

2\) Was an actual change in transcription in the *lacI* mutant seen or is this simply presumed? (And why is high expression of YcbB toxic (subsection "YcbB-mediated β-lactam resistance", first paragraph)? The authors may not know, of course, but it would be useful to briefly speculate based on the authors understanding).

3\) Was a change in ppGpp levels in the tRNA synthetase mutants that were essential for the phenotype actually measured? As there are broad effects of altering ppGpp pools, the lack of direct connection detracts from the perceived robustness of the results and the model proposed. There are also effects on the cell of mistranslation.

4\) When the glycosyltransferase (GT) activity of PBP1B is blocked by mutation, its transpeptidase (TP) activity also decreases substantially or disappears (Egan et al., 2015). This means that the PBP1B-E^233^ mutant lacks both GT and TP activities. Thus, even if the GT enzymatic domain is \"inactivated independently\" (subsection "Identification of the glycosyltransferase partner of YcbB", second paragraph), it is unclear how the authors can claim that only \"the GT activity of PBP1b.... is required for.... β-lactam resistance\" (second paragraph), or that this GT activity \"is necessary and sufficient\" (third paragraph) \[Reference: Egan, A. J. F., J. Biboy, I. van\'t Veer, E. Breukink & W. Vollmer, (2015) Activities and regulation of peptidoglycan synthases. Philosophical Transactions of the Royal Society of London B: Biological Sciences 370: 20150031\].

5\) In the subsection \"L,D-transpeptidase activity of YcbB\", a schematic of this reaction is shown, but no biochemical data is presented showing that the protein actually exhibits this enzymatic activity. What is the basis for this claim? Without the underlying data the reader does not know anything about the reaction or its rate. (Also, how active is YcbB when compared to similar L,D or D,D enzymes?)

6\) In the subsection \"Inactivation of YcbB by β-lactams\", no biochemical data is presented to support this claim. Without this data the reader does not know anything about the rate or extent of inhibition.

10.7554/eLife.19469.021

Author response

*\[...\] Essential revisions:*

*A major limitation of the manuscript in its current form is that are some gaps in logic and omissions of critical data. For example, there is broad interest in the field in antibiotic resistance, and the central theme of this paper is the ampicillin-resistant generation of a complete cell wall. However, this reviewer is unfamiliar with that happening in nature, and as a result, most β-lactam related resistance is mediated by drug modifying enzymes and efflux -- is that the case? For the sake of a balanced perspective, the authors should discuss any evidence that this bypass occurs, or if not, why not?*

In *E. coli*, as in Gram-negative bacteria, resistance of clinical isolates to β-lactams is mostly due to a combination of β-lactamases, efflux, and reduced penetration of the drug across the outer membrane. In Gram-positive bacteria, reduced affinity of the targets and β-lactamase production are the most frequent mechanisms.

The bypass resistance mechanism mediated by L,D-transpeptidases has not been reported to emerge in response to the selective pressure of antibiotics in natural conditions. However, L,D-transpeptidases have a major role in peptidoglycan synthesis in members of the genus *Mycobacterium* since 70% to 80% of the cross-links are of the 3→3 type (1, 2). Bypass of the D,D-transpeptidase activity of the PBPs has occurred in this phylum, although the modification of the peptidoglycan assembly pathway is ancient and most probably not linked to the selective pressure of β-lactams. The determinants of β-lactam resistance in the mycobacteria are complex. Resistance is not solely determined by the targets since the mycomembrane limits access of the drugs to the periplasm. In addition, production of a broad spectrum β-lactamase (BlaC) limits the efficacy of most, if not all, β-lactams, but BlaC is inactivated by the β-lactamase inhibitor clavulanate (3, 4). Regarding the targets, insertional inactivation of the gene encoding the L,D-transpeptidase Ldt~Mt2~ results in increased killing of *M. Tuberculosis* by the amoxicillin-clavulanate combination (5). However, L,D-transpeptidases are not the only target of β-lactams in *M. Tuberculosis* since the essential tetrapeptide is produced by D,D-carboxypeptidases that are inhibited by β-lactams (6). In conclusion, mycobacteria are the only naturally occurring bacteria in which L,D-transpeptidases have a role in resistance in natural isolates. Of note, we have shown that other members of the *Actinomycetales* produce a peptidoglycan containing similar amounts of 4→3 and 3→3 cross-links (7). In these bacteria, the L,D-transpeptidases may contribute to tolerance rather than resistance to glycopeptide antibiotics, which inhibit peptidoglycan synthesis by a mechanism unrelated to that of β-lactams (7).

In *E. faecium,* emergence of resistance to β-lactams by the bypass mechanism has been reported in laboratory conditions (8), as described in the current manuscript for *E. coli*. The large number of mutations observed in the mutants of *E. faecium* (9), combined to the slower growth associated with bypass of the PBPs (10), and the ease of selection of β-lactam resistant mutants by modification of low-affinity PBP5 (11) may limit the emergence of the bypass resistance mechanism in *E. faecium*.

In *E coli*, emergence of resistance was shown in the current manuscript to only require an increase in (p)ppGpp synthesis provided that YcbB is produced at an appropriate level. As indicated in the 3^rd^ paragraph of the Results section, attempts to select ampicillin-resistant derivatives of the strain M1~cured~ were negative (survivor frequency \< 10^-9^). Thus, YcbB is not produced at a sufficient level for bypass of the PBPs in wild-type *E. coli* and the *ycbB* promoter could not be activated in a single selection step. This could be one of the key limitations for the emergence of the bypass mechanism in *E. coli*. In addition, the *E. coli* mutants described in our study displayed slowed growth, as reported in *E. faecium*, but the underlying mechanisms were different as increased production of (p)ppGpp is not involved in *E. faecium* (9, 12).

These observations indicate that the 3→3 mode of peptidoglycan cross-linking has a large fitness cost for exponential growth in laboratory conditions. It is therefore likely that a fitness cost is also associated with this mode of peptidoglycan cross-linking in natural conditions, although the possibility for acquisition of compensatory mutations has not been studied. Lessons from the past have indicated that certain resistance mechanisms considered to be highly unlikely have emerged after decades of antibiotic use (e.g. glycopeptides resistance due to modification of the structure of peptidoglycan precursors). Discussing the likelihood of the emergence of the bypass mechanism is highly speculative.

*In terms of leaps of logic in the experimentation that require further explanation:*

*1) As it currently reads (subsection "YcbB-mediated β-lactam resistance", first paragraph), it appears that selection for both resistance to 500 μg/ml IPTG induction and resistance to 32 μg/ml ampicillin were performed simultaneously. Is this correct? If so, the rationale as well as rate of mutation should be better explained and documented, as this is central to the manuscript.*

The reviewer is correct in describing the conditions for selecting mutant M1. The survival rate was ca. 10^-9^ for the selection of mutants on media containing 500 µM of IPTG and 32 µg/ml of ampicillin. Induction of the gene encoding YcbB with 50 µM IPTG is sufficient for resistance, whereas higher levels of YcbB production are toxic. The LacI mutation reduced the expression of YcbB providing the right amount of YcbB.

The mutant M1 selected under those conditions harbored two mutations as determined by genetic analyses and confirmed by whole genome sequencing. The acquisition of two mutations in a single step might seem surprising if one considers the rate of mutations in *E. coli* (in the order of 1 X 10^-3^ per genome and per generation; (13)). However, several factors may increase the survival rate and/or the mutation frequency (see (14) for a discussion). It is also worth noting that one of the two mutations occurred on a gene carried by a multicopy plasmid (*lacI*) and that the mutation is likely to be dominant. We therefore think that the selection of survivors with two mutations did not involve any mutator phenotype, in agreement with the presence of only two mutations in the entire genome, as established by whole genome sequencing. We did not further comment on the basis for the frequency of survivors with two mutations in *E. coli* since this is beyond the scope of the current manuscript.

*2) Was an actual change in transcription in the lacI mutant seen or is this simply presumed? (And why is high expression of YcbB toxic (subsection "YcbB-mediated β-lactam resistance", first paragraph)? The authors may not know, of course, but it would be useful to briefly speculate based on the authors understanding).*

The location of the amino acid substitution in LacI clearly indicates that binding of IPTG to the repressor is impaired thereby decreasing transcription of *ycbB* in response to the inducer. We do not think that this aspect requires experimental evidence in the context of the current manuscript. Regarding the toxic effect of YcbB, we have experimentally shown that induction of *ycbB* by IPTG in excess of 50 µM fully inhibits growth of the *E. coli* strains only producing the wild-type LacI repressor. Like high-molecular weight PBPs (D,D-transpeptidases), YcbB harbors a putative N-terminal membrane anchor. The toxicity generated by overproduction of YcbB may therefore be due to the insertion of the protein into the cytoplasmic membrane. Evidence for this mechanism of toxicity has been reported for overproduction of PBP2 in *E. coli* (15).

A sentence has been added to the revised version of the manuscript:

"The toxicity associated with high-level production of YcbB may be linked to the putative membrane anchor of the protein, as demonstrated for PBP2 in *E. coli* (15)." Modifications appear in the Results section.

*3) Was a change in ppGpp levels in the tRNA synthetase mutants that were essential for the phenotype actually measured? As there are broad effects of altering ppGpp pools, the lack of direct connection detracts from the perceived robustness of the results and the model proposed. There are also effects on the cell of mistranslation.*

We haven't compared the ppGpp pools. An increase in the ppGpp pool in response to impaired aminoacylation of tRNAs has been documented in several publications (e.g. (16)). The fact that the mutants described in [Table 4](#tbl4){ref-type="table"} harbor mutations in various aminoacyl-tRNA genes and that one of them harbors a mutation in the promoter region of the IleRS gene clearly indicates that the mutations affect the level of amino acylation. In addition, we have shown that expression of *relA'* has the same effect on expression of resistance. In this case, the pool of ppGpp has been determined (17). Together, these data are sufficient to conclude that an increase in the production of ppGpp results in resistance. We agree with the reviewer that direct determination of the ppGpp pool would provide an estimate of the intracellular concentration of the alarmone that is required for growth in the presence of ampicillin when YcbB is the only functional transpeptidase. We anticipate that the changes in the level of ppGpp that enable both resistance and growth might be rather subtle and think that this additional aspect, which is technically challenging, is not required to support the main conclusions of our study.

Regarding the effect on mistranslation, our experiment with RelA' is performed in the absence of amino acid starvation. According to Sorensen et al. (18), the fidelity of translation is decreased in a *relA* strain, which is unable to down regulate mRNA synthesis with (p)ppGpp in response to amino acid starvation. Our mutants are expected to produce elevated ppGpp levels and are therefore not expected to display a decrease in the fidelity of translation.

*4) When the glycosyltransferase (GT) activity of PBP1B is blocked by mutation, its transpeptidase (TP) activity also decreases substantially or disappears (Egan et al., 2015). This means that the PBP1B-E^233^ mutant lacks both GT and TP activities. Thus, even if the GT enzymatic domain is \"inactivated independently\" (subsection "Identification of the glycosyltransferase partner of YcbB", second paragraph), it is unclear how the authors can claim that only \"the GT activity of PBP1b.... is required for.... β-lactam resistance\" (second paragraph), or that this GT activity \"is necessary and sufficient\" (third paragraph). (Reference: Egan, A. J. F., J. Biboy, I. van\'t Veer, E. Breukink & W. Vollmer, (2015) Activities and regulation of peptidoglycan synthases. Philosophical Transactions of the Royal Society of London B: Biological Sciences 370: 20150031.)*

The reviewer is correct in stating that introduction of the E^233^M substitution in PBP1b is likely to impair the transpeptidase activity of PBP1b since in vitro analyses of PBP1a have shown that inactivation of the transglycosylase domain prevents formation of cross-links, although the transpeptidase domain remains functional with respect to acylation by β-lactams (19). Thus, we acknowledge the fact that the first version of the manuscript was erroneous in stating that we had selectively inactivated the transglycosylase and transpeptidase domains of PBP1b. We have therefore rephrased the entire paragraph (subsection "Identification of the glycosyltransferase partner of YcbB", second paragraph) and cited the review article by Egan et al.(as suggested by the reviewer; (20)) and the references corresponding to the original publications on this topic (19, 21-23). We have also separately described our results obtained for production of PBP1b E^233^M in *E. coli* cells and mentioned the caveat for the potential loss of transpeptidase activity previously observed in vitro. However, we have maintained the conclusion that since this conclusion only requires to demonstrate that the transpeptidase domain is unessential, as experimentally shown in the preceding paragraph based on the S^510^A substitution.

*5) In the subsection \"L,D-transpeptidase activity of YcbB\", a schematic of this reaction is shown, but no biochemical data is presented showing that the protein actually exhibits this enzymatic activity. What is the basis for this claim? Without the underlying data the reader does not know anything about the reaction or its rate. (Also, how active is YcbB when compared to similar L,D or D,D enzymes?)*

The evidence is based on the identification of the reaction products (two dimers and a tripeptide) by mass spectrometry and determination of their structure by tandem mass spectrometry. The observed and calculated masses of the products were included in the first version of the manuscript. As requested by the reviewer, we have added a figure ([Figure 5](#fig5){ref-type="fig"}) showing the actual data. Regarding the rate of the reaction, the intensity of the peaks indicates that ca. 85% of the disaccharide-tetrapeptide substrate has been converted to products in 2 hours. Dimers were more abundant than the tripeptide produced by the L,D-carboxypeptidase activity of YcbB. More detailed quantitative assessment is not feasible since the dimer Tri-Tri can result from the formation of the dimer Tri-Tetra followed by cleavage of D-Ala^4^ or from the formation of a dimer using a disaccharide-tripeptide as the acyl acceptor. The kinetics are therefore too complex to provide rates for the L,D-carboxypeptidase and L,D-transpeptidase reactions. Similar analyses performed by Triboulet *et al.* (24) with the L,D-transpeptidase of *E. faecium* (Ldt~fm~) provided similar results with a seemingly lower L,D-transpeptidase to L,D-carboxypeptidase ratio (1.3) and higher overall activity. The differences are however not extensive (\< 3 fold) and differences in the assays preclude accurate comparisons. In particular, the two substrates used for Ldt~fm~ were exclusively used either as an acyl donor or an acyl acceptor. A similar assay could not be developed for YcbB due to differences in the structure of the peptidoglycan from *E. faecium* and *E. coli*. Comparison with D,D-transpeptidases (PBPs) is not feasible since these enzymes are not active with disaccharide peptides, requiring coupling with transglycosylation and use of a lipid II intermediate as the substrate.

*6) In the subsection \"Inactivation of YcbB by β-lactams\", no biochemical data is presented to support this claim. Without this data the reader does not know anything about the rate or extent of inhibition.*

As requested by the reviewer, we have added a figure ([Figure 7](#fig7){ref-type="fig"}) showing the extent of acylation of YcbB by imipenem, meropenem and ceftriaxone.
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[^1]: \*BW25113Δ4 is a derivative of *E. coli* BW25113 that does not harbor the *ynhG*, *ybiS*, *erfK*, and *ycfS* genes encoding YcbB paralogues. M1 is a β-lactam-resistant mutant of BW25113Δ4 harboring pJEH11-1(*ycbB*). M1~cured~ is a derivative of M1 resulting from the spontaneous loss of pJEH11-1(*ycbB*). Plasmid pJEH12(*ycbB*) was obtained by replacing the origin of replication (ColE1) and resistance marker (kanamycin) of pJEH11-1(*ycbB*) by the p15A replication origin and tetracycline resistance marker of plasmid pACY184. The L,D-transpeptidase gene *ycbB* of pJEH11-1 and pJEH12 are expressed under the control of the IPTG-inducible *trc* promoter and regulated by the LacI Arg^127^Leu repressor.

[^2]: ^†^Combination of amoxicillin (20 µg) and clavulanate (10 µg).

[^3]: ^‡^Combination of piperacillin (75 µg) and tazobactam (10 µg).

[^4]: ^§^ND, not detected as the strains grew at the contact of the disk.

[^5]: ^\*^Mutants of the Keio collection harboring a kanamycin-resistance gene cassette in place of the indicated gene.

[^6]: ^†^Frequency of survivors obtained by plating 10^9^ colony forming units on agar containing ceftriaxone (32 µg/ml) and IPTG (50 µM). Values are the median from 2 to 8 experiments.

[^7]: ^‡^The glycosyltransferase (GT) module of PBP1b was selectively inactivated by the E^233^M amino acid substitution.

[^8]: ^§^The transpeptidase (TP) module of PBP1b was selectively inactivated by the S^510^A substitution.

[^9]: *E*. *coli* CS801-4 harbors deletions of genes *pbp4*, *5*, *6*, *7*, *mrcA*, *ampH*, *ampC*, and *dacD*.

[^10]: ^\*^13-base pair deletion (positions 22,373 to 22,385).

[^11]: Ap, ampicillin; IleRS, isoleucine-tRNA synthetase; Me, mecillinam.

[^12]: ^\*^Minimal inhibitory concentrations were determined by the agar dilution method with an inoculum of 10^5^ colony forming units per spot in brain heart infusion agar after 24 hr of incubation at 37°C. The same results were obtained with 10^4^ and 10^6^ colony forming units, indicating that YcbB in combination with elevated (p)ppGpp rendered the bulk of the population resistant.

[^13]: ^†^Induction was performed with 50 mM IPTG, 1% arabinose (Ara), and a combination of both inducers (IPTG+Ara). IPTG induces expression of the *ycbB* gene of plasmids pJEH12(*ycbB*) and pKT2(*ycbB*). Arabinose induces expression of *relA'* encoding the first 455 residues of RelA.
